Novo Nordisk reported that its combination candidate CagriSema beat semaglutide in a Phase 3 diabetes study, showing superior reductions in blood glucose and greater weight loss. The company enrolled more than 2,700 people with type 2 diabetes and reported numerically stronger efficacy on both glycemic and weight endpoints. Novo’s results add urgency to the competitive landscape in metabolic medicines, where Lilly’s Zepbound and Novo’s own portfolio are jockeying for market leadership. The Phase 3 readout strengthens Novo’s regulatory filings and positions CagriSema as a next‑generation combination to challenge existing GLP‑1 standards of care.